logo-loader
viewGenprex, Inc.

Full interview: CEO Rodney Varner sees newly licensed therapy as an 'opportunity we couldn't pass up'

 (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a therapy that could have the potential to treat Type 1 and Type 2 diabetes.

Varner says the newly licensed therapy was an 'opportunity we couldn't pass up' because of its large market opportunity and 'massive' medical need.

Quick facts: Genprex, Inc.

Price: 4.38 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $121.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Castillo Copper's Ged Hall updates on key assets and progress on London dual...

Ged Hall works with London stockbroker SI Capital and is also a non-exec director at Castillo Copper Ltd's (ASX:CCZ). He discusses how the two came to work together as well as updates on what Castillo's doing as far as the Mt Oxide project in Queensland, Australia. 

3 hours ago

2 min read